Objective: Platinum compounds play pivotal roles in treatment for squamous cell carcinoma of the head and neck. The objective was to evaluate the efficacy of S-1 monotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy. Methods: We retrospectively analyzed 39 consecutive patients with recurrent or metastatic squamous cell carcinoma of the head and neck who received S-1 monotherapy after failure of platinum-based chemotherapy or chemoradiotherapy at the Shizuoka Cancer Center between August 2003 and October 2010. S-1 was given orally twice daily (80 mg/m 2 /day) for 28 days followed by a 14-day rest. Results: The median follow-up period in survivors was 31.5 months. Among 38 patients with measurable lesions, 9 (24%) showed partial response and 15 (39%) showed stable disease. The median progression-free survival was 4.9 months and the median overall survival was 13.2 months. The median progression-free survival for oropharyngeal cancer (n ¼ 7) was significantly longer than for other cancers (n ¼ 32) (14.9 vs. 4.7 months, P ¼ 0.035). The response rate in patients with a recurrence-free interval since the last platinum administration .6.0 months was significantly better than with a recurrence-free interval ,6.0 months (40 vs. 13%, P ¼ 0.0102). Recurrence-free interval .6.0 months also showed a significantly better progression-free survival (6.0 vs. 2.6 months, P ¼ 0.045). The frequency of Grade 3/4 toxicities was less than 10%. Conclusions: S-1 monotherapy shows promising signs of efficacy and tolerability in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy in this retrospective cohort and warrants further investigation in this population.
INTRODUCTION
Head and neck cancers are mostly located in the oral cavity, pharynx and larynx (1) , and . 90% of such cancers are squamous cell carcinomas histologically (2, 3) . Most patients with squamous cell carcinoma of the head and neck (SCCHN) present with locally or regionally advanced disease (4, 5) . Single-agent cisplatin (CDDP) with concurrent radiotherapy is a standard non-surgical treatment for locally advanced SCCHN patients (6 -8) and is also considered the standard adjuvant therapy for high-risk postoperative patients (9 -11) . Thus, platinum compounds play pivotal roles in initial multidisciplinary therapy for SCCHN. However, 20 -30% of the patients with SCCHN have local recurrence or distant metastasis after initial therapy.
The treatment goals for recurrent or metastatic (R/M)-SCCHN are symptom management and prolongation of survival (1). For patients not suitable for local therapies, treatment options have been limited to systemic chemotherapy and best supportive care (12) . However, the prognosis for patients with R/M-SCCHN is extremely poor, despite the use of platinumbased chemotherapy. Furthermore, alternative therapeutic regimens for patients with R/M-SCCHN are limited once platinum-based treatment has failed.
S-1 is an oral anticancer drug that combines tegafur, a prodrug of fluorouracil (FU), with 5-chloro-2,4-dihydropyrimidine (CDHP) and potassium oxonate in a molar ratio of 1:0.4:1. CDHP reversibly antagonizes the activity of dihydropyrimidine dehydrogenase, the rate-limiting enzyme for the degradation of FU. Therefore, high concentrations of FU in serum and tumors are maintained for prolonged periods. Potassium oxonate blocks the phosphorylation of FU in the gastrointestinal tract, decreasing gastrointestinal toxic effects, the largest dose-limiting toxicity of FU (13) .In Japan, the use of S-1 is approved for the treatment of gastric cancer, colorectal cancer, non-small cell lung cancer, breast cancer, pancreatic cancer, and head and neck cancer. Although studies of small numbers of patients have reported the efficacy of S-1 monotherapy for head and neck cancer (14 -16) , it remains unclear how S-1 monotherapy is effective and tolerable for patients with R/M-SCCHN. This retrospective study aimed to evaluate the efficacy and safety of 4 weeks administration of S-1 monotherapy followed by a 2-week interval, in the treatment of patients with R/M-SCCHN after failure of platinumbased chemotherapy.
PATIENTS AND METHODS

PATIENTS
Patients fulfilling the following criteria were enrolled: (i) histologically confirmed SCCHN; (ii) S-1 monotherapy according to the following treatment schedule; (iii) previous platinum (CDDP/carboplatin/nedaplatin)-based chemotherapy either as definitive chemoradiation for locally advanced disease or post-operative adjuvant chemoradiation or as a first-line chemotherapy after recurrence before the use of S-1; (iv) documented tumor progression [progressive disease (PD)] during platinum-based treatment or recurrence after platinum-based chemoradiotherapy. For this study, appropriate approvals were obtained from the institutional review committee.
TREATMENT SCHEDULE S-1 was orally administered twice daily after a meal for 4 weeks followed by a 2-week rest, at the following doses 
STATISTICAL ANALYSIS
Progression-free survival (PFS) was calculated from the date of the first administration of S-1 to the earliest date when the treatment was discontinued for PD. If the treatment was discontinued due to reasons other than PD, PFS was calculated from the date of the first administration of S-1 to the date when the disease worsened or when the patient died from any cause. Overall survival (OS) time was calculated from the date of the first administration of S-1 to the date of death from any cause or to the last date of confirmed survival. Survivals were analyzed by the Kaplan -Meier method. Survival curves were compared using a log-rank test. Two-sided P values ,0.05 were considered statistically significant.
RESULTS
PATIENT CHARACTERISTICS
Sixty-three consecutive SCCHN patients were treated with S-1 monotherapy according to the above treatment schedule at Shizuoka Cancer Center between August 2003 and October 2010. Of these 63 patients, 45 were R/M-SCCHN patients who were previously treated with platinum-based chemotherapy consisting of CDDP (n ¼ 42), carboplatin (n ¼ 6) or nedaplatin (n ¼ 4) in the setting of either definitive chemoradiation (n ¼ 35), postoperative adjuvant chemoradiation (n ¼ 3) or first-line chemotherapy after recurrence (n ¼ 15). Of these 45 patients, 6 were excluded from the study because there was no documented PD during platinum-based treatment or recurrence after platinum-based chemoradiotherapy. Thus, the population in our study comprised 39 patients.
1352
S-1 for platinum-treated SCCHN patients Evaluation of disease recurrence or progression at the first administration of S-1 revealed that 33 (85%) patients had distant metastasis (Table 1) . Definitive chemoradiation was performed in 31 patients (79%) as the initial treatment. Of these, CDDP was administered as the initial concurrent radiotherapy for 21 patients (54%), whereas CDDP plus 5-FU was given for 10 patients (26%). Of the seven patients (18%) who underwent surgery as the initial treatment, three patients received adjuvant chemoradiation using CDDP and four patients received platinum after recurrence. Regarding the number of prior regimens before S-1, 27 patients (69%) previously received only one regimen including original therapy, and 18 patients (46%) were previously treated with 5-FU. Twenty-four patients (62%) had PD during platinumbased treatment or recurrence ,6 months after platinumbased chemoradiotherapy (designated as Cohort A), while 15 patients (38%) had recurrence .6 months after the last platinum administration (designated as Cohort B).
TREATMENT COURSE A total of 187 courses were administered, with a median of four courses per patient (range: 1 -30). The median of the treatment duration was 153 days. Dose reduction of the initial dose was required in six patients because of renal dysfunction and in three patients because of aging and performance status (PS). Dose reductions from the second course were required in eight patients (21%) due to the development of anorexia, diarrhea, vomiting, fatigue, neutropenia, renal dysfunction, mucositis, infection, loss of body weight or thrombocytopenia. S-1 monotherapy was discontinued in 29 patients (74%) because of disease progression and in 5 patients (13%) because of the development of non- hematological toxicities such as colitis, nausea, fatigue and pneumonia.
EFFICACY OUTCOMES
Response was evaluated among the 38 patients who had target lesions. Overall, a PR was observed in 24% of patients (9/38). Fifteen patients had SD, and the tumor control rate (PR plus SD) was 63% (24/38) according to RECIST ( Table 2 ). The response rate (RR) was better in patients whose primary sites were the oropharynx (n ¼ 7) and the oral cavity (n ¼ 8) than in those with other primary sites (n ¼ 23), (43 vs. 38 vs. 13%, P ¼ 0.1935). The RR was significantly better in patients who had received only one regimen before S-1 (n ¼ 26) than in those receiving more than two regimens (n ¼ 12) (31 vs. 8%, P ¼ 0.013). With respect to recurrence-free interval (RFI) since the last platinum administration, the RR was significantly better in Cohort B (n ¼ 15) than in Cohort A (n ¼ 23) (40 vs. 13%, P ¼ 0.0102). No significant differences were observed in the RR with respect to prior treatment with (n ¼ 18) or without (n ¼ 20) 5-FU.
SURVIVAL
The median follow-up period in survivors was 31.5 months. The median PFS and OS were 4.9 and 13.2 months, respectively (Figs 1 and 2 ). The median PFS for oropharyngeal cancer (n ¼ 7) was 14.9 months, which was significantly longer than the 4.7 months for other cancers (n ¼ 32) [hazard ratio (HR) ¼ 0.32, 95% confidence interval (CI): 0.11 -0.92, P ¼ 0.035; Table 3 ]. No significant differences in PFS with respect to prior treatment with (n ¼ 18) or without (n ¼ 21) 5-FU were observed (Table 3) . Among 18 patients with prior treatments containing 5-FU, we defined 5-FU failure as cancer with PD during 5-FU-based treatment or recurrence ,6 months after 5-FU-based treatment. Ten patients with 5-FU failure showed a trend toward shorter PFS than the remaining eight patients with 5-FU non-failure (HR ¼ 1.64, 95% CI: 0.60 -4.45, P ¼ 0.333). Furthermore, consistent with the above-mentioned efficacy outcome, PFS for the patients in Cohort B (n ¼ 15) was significantly longer than that for patients in Cohort A (n ¼ 24) (6.0 vs. 2.6 months, P ¼ 0.045; Table 3 ). A Cox's proportional hazards model revealed that the relative risk of death for patients with oropharyngeal cancer was 1354 S-1 for platinum-treated SCCHN patients 0.27 (95% CI: 0.08 -0.86) compared with patients with other cancers (P ¼ 0.027; Table 3 ). However, RFI since the last platinum administration was not found to be an independent factor for survival.
TOXICITY
The worst toxicities observed during the treatment periods are listed in Table 4 . Grade 3 infection and anorexia occurred in two patients each. Overall, S-1 was not associated with severe hematologic and non-hematologic toxicities. All patients remained outpatients throughout the treatment period. No treatment-related deaths occurred.
DISCUSSION
In this study, a single-agent S-1 regimen (80 mg/m 2 /day for 4 weeks followed by a 2-week rest) appeared to have promising signs of efficacy and an acceptable safety profile for the treatment of R/M-SCCHN patients after failure of platinumbased chemotherapy. A few studies reported the efficacy and safety of S-1 monotherapy for recurrent head and neck cancer (14 -16) . However, these studies need to be interpreted with caution for several reasons. First, the patients in these studies were histologically heterogeneous and included non-SCC patients. Secondly, in some studies, S-1 was administered for 2 weeks followed by a 1-week rest, which is not a standard treatment schedule for the initial use of S-1 for patients in good general status. Most importantly, the subgroup analysis was not performed according to prior chemotherapy or chemoradiotherapy, focusing particularly on prior platinum use.
So far, platinum-based chemotherapy is the usual first-line treatment for inoperable R/M-SCCHN. Although the survival benefit of the combination of 5-FU with platinum is controversial, platinum is often combined with FU in systemic chemotherapy (17) . However, because the sequence or combination pattern of chemotherapeutic agents is complex in the multidisciplinary therapy for SCCHN, it could be argued that the population with R/M-SCCHN is heterogeneous with respect to treatment history before recurrence. Furthermore, several studies in other cancer types have suggested the importance of the interval since the last treatment as a predictive marker of responsiveness to salvage chemotherapy (18, 19) . Therefore, our study focused on R/M patients who had failed platinum-based therapy as concurrent or adjuvant chemoradiotherapy or as first-line chemotherapy after recurrence. The efficacy of S-1 monotherapy and Our results demonstrated no significant differences in S-1 efficacy among patients with or without prior treatment with 5-FU, although a slight trend toward poorer efficacy was shown among patients with PD during 5-FU-based treatment or with recurrence ,6 months after 5-FU-based treatment. This suggests that the use of S-1, a prodrug of 5-FU, has benefits regardless of the prior use of fluoropyrimidine-based chemotherapy in SCCHN.
Since there is no consensus on the definition of RFI since the last platinum administration for platinum-refractory disease, the duration of the platinum-free interval for which the secondary platinum is expected to have efficacy is unclear. Therefore, it depends on the physician to choose whether platinum or alternative agents are to be introduced for patients with R/M-SCCHN who were previously treated with platinum-based chemotherapy. Our study demonstrated that patients whose disease recurred with an RFI of .6 months had a better RR and longer PFS in S-1 monotherapy than patients with earlier relapse after platinum therapy, suggesting multidrug resistance. These outcomes suggest that chemosensitivity to S-1 in R/M-SCCHN correlates with the RFI since the last platinum-based chemotherapy. S-1 monotherapy appears to be a promising option especially for R/M-SCCHN recurring after a long platinum-free interval.
However, we need to take care of renal toxicity when using S-1 for the patients with R/M-SCCHN after progression on platinum-based chemotherapy. Some reports have shown that impaired renal function would reduce CDHP clearance, which results in prolonged exposure to high concentration of plasma 5-FU and thus myelosuppression. Therefore, dose and schedule adjustment is required according to patients' renal function.
The multivariate analysis revealed that the oropharynx as a primary site is associated with a significantly better outcome of S-1 therapy, independent of other factors such as age, gender, PS, R/M sites and prior regimen. Our analysis also supports the case report from Homma et al. (20) that suggested that long-term histological CR persisted following treatment with S-1 in a recurrent oropharyngeal SCC. While the mechanism of sensitivity to S-1 in oropharyngeal cancer is unclear, this finding may be consistent with several recent studies reporting a high frequency of human papillomavirus (HPV) DNA presence in oropharyngeal cancers and improved outcomes in HPV-associated oropharyngeal cancer (21 -24) .
Although the current study has limitations such as the use of small retrospective data, performance at a single center and a heterogeneous treatment history, this is the first report to evaluate the efficacy of S-1 monotherapy in patients with R/M-SCCHN after failure of platinum-based chemotherapy. Our observations support further prospective investigation of S-1 for patients with R/M SCCHN in the platinum-refractory setting. In conclusion, S-1 monotherapy is a feasible and active systemic chemotherapy for the palliative treatment of R/M-SCCHN. Primary tumor sites and prior chemotherapeutic regimen should be considered in the use of S-1 in this setting.
